Sponsor or institution

Clinical trials and research at SystImmune Inc.

• 6Clinical trials
• 1New in 30 days
• 16Countries

Newest trials

All recruiting trials (6)

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• BL-M14D1 for people with advanced small cell lung cancer and other neuroendocrine tumors.

  This trial will try BL-M14D1 in adults with locally advanced or metastatic small cell lung cancer or other high-grade neuroendocrine tumors to see if it is safe and helps control the cancer after standard treatments have failed.

  Recruiting at 26 sites Phase 1 SystImmune Inc. · Huntsville, Alabama and 30 other locations · NCT07080242

• Evaluating BL-M07D1 for HER2 Expressing Solid Tumors

  This study is testing a new treatment called BL-M07D1 to see if it is safe and effective for people with advanced solid tumors that have a specific protein called HER2 after they have tried other treatments.

  Recruiting at 24 sites Phase 1 SystImmune Inc. · Birmingham, Alabama and 25 other locations · NCT06293898

• Evaluating BL-B01D1 for patients with advanced lung and solid tumors

  This study is testing a new treatment called BL-B01D1 to see if it is safe and effective for people with advanced lung cancer and other solid tumors.

  Recruiting at 37 sites Phase 1 SystImmune Inc. · Beverly Hills, California and 36 other locations · NCT05983432

Quick answers

How many clinical trials run by SystImmune Inc. are recruiting right now?

6, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 16 countries. The most sites are in United States (6 trials), France (2 trials), Georgia (2 trials), Italy (2 trials), Spain (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →